Clinical trial NCT00233675: Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
Official title: A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: General Anxiety Disorder
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2005-10-06
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).


Eligibility criteria: Not available at time of registration

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Mesa
country: United States
facility: Pivotal Research Center
state: Arizona
city: Beverly Hills
country: United States
facility: Southwestern Research
state: California
city: Newport Beach
country: United States
facility: Pharmacology Research Institut
state: California
city: Northridge
country: United States
facility: Pharmacology Research Institut
state: California
city: Orange
country: United States
facility: Pacific Clinical Research Medi
state: California
city: San Diego
country: United States
facility: Radiant Research San Diego
state: California
city: San Diego
country: United States
facility: Affiliated Research Institute
state: California
city: Denver
country: United States
facility: Radiant Research Denver
state: Colorado
city: Farmington
country: United States
facility: University of Connecticut
state: Connecticut
city: Jacksonville
country: United States
facility: Clinical Neuroscience Solution
state: Florida
city: West Palm Beach
country: United States
facility: Clinical Neuroscience Solution
state: Florida
city: Smyrna
country: United States
facility: Carman Research
state: Georgia
city: Edwardsville
country: United States
facility: Cunningham Clinical Research
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Farmington Hills
country: United States
facility: Summit Research Network Farmin
state: Michigan
city: Clementon
country: United States
facility: CNS Research Institute
state: New Jersey
city: Brooklyn
country: United States
facility: Social Psychiatry Research Ins
state: New York
city: New York
country: United States
facility: Fieve Clinical Services, Inc.
state: New York
city: New York
country: United States
facility: Medical and Behavioral
state: New York
city: New York
country: United States
facility: Medical Research Network
state: New York
city: Raleigh
country: United States
facility: Richard Weisler, MD and Assoc
state: North Carolina
city: Portland
country: United States
facility: Summit Research Network Inc.
state: Oregon
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Charleston
country: United States
facility: South East Health Consultants
state: South Carolina
city: Bellaire
country: United States
facility: Claghorn-Lesem Research
state: Texas
city: Salt Lake City
country: United States
facility: Radiant Research Salt Lake
state: Utah
city: Falls Church
country: United States
facility: Comprehensive Neuroscience Of
state: Virginia
city: Seattle
country: United States
facility: Summit Seattle Boren
state: Washington
Study officials:
affiliation: Cephalon
name: Charles Brown, MD
role: STUDY_DIRECTOR
References: